MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, February 13, 2017

Ampyra Works Long-Term for MS Patients With Gait Disturbance

Click here to receive MS news via e-mail

Feb 9, 2017

Long-term treatment with prolonged-release fampridine (Ampyra) offered persistent clinical and subjective benefits in walking function in gait-impaired patients with multiple sclerosis (MS), researchers reported.

In an extension study of the FAMPKIN trial, MS patients had an 11.5% improvement in walking speed, a 10.7% improvement in endurance, and a 6.1-point improvement in self-perceived ambulatory function over baseline during the first open-label year of treatment, according to Linard Filli, PhD, of University Hospital Zurich, and colleagues.

Those effects remained stable during a follow-up year of double-blind controlled treatment, with improvements in those respective endpoints of 13.1%, 12%, and 7.4 points compared with placebo, they reported online in Neurology.

Read More

MS Views and News
Providing educational information, resources and services for those affected by MS, globally

No comments: